Generex Biotechnology Corporation
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph Moscato
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10102 USA Today Way Miramar FL United States of America 33025
- IPO Date
- Feb 5, 1998
- CIK
- 0001059784
- Website
- generex.com
- Similar Companies
- Business
- Generex Biotechnology Corporation (GNBT) develops and commercializes drug delivery systems and technologies, with a focus on oral (buccal) administration of large-molecule drugs including proteins, peptides, monoclonal antibodies, hormones, and vaccines for metabolic and immunological diseases; core products and services encompass Generex Oral-lyn (buccal insulin spray for type 1 and type 2 diabetes, approved in Ecuador), Glucose RapidSpray, BaBOOM! Energy Spray, Crave-NX, AE37 (Ii-Key-HER2 peptide vaccine in phase II for breast, prostate, and bladder cancers), immunotherapeutic vaccines, Excellagen wound conforming matrix, extracellular matrix hydrogel for ulcerative colitis, regenerative medicine therapeutics including exosomes and placenta-derived products, point-of-care and laboratory diagnostics for infectious diseases such as HIV, tuberculosis, malaria, hepatitis B/C, and syphilis, foot and ankle surgical kits with plates, screws, and tools, orthopedic implants, biologics, durable medical equipment, and ancillary health services in eyecare, podiatry, chronic care management via subsidiaries NuGenerex Immuno-Oncology, NuGenerex Health, NuGenerex Regenerative Medicine, NuGenerex Diagnostics, Olaregen Therapeutix, and NuGenerex Distribution Solutions. The company, founded in 1983 and headquartered in Miramar, Florida, with prior base in Toronto, Canada, operates primarily in the United States, Canada, and Ecuador through distributors and retail chains, targeting patients with diabetes, cancer, infectious diseases, and wound care needs alongside physician networks including orthopedic surgeons and podiatrists. Recent developments include a January 2024 bankruptcy court approval for asset sales, building on prior 2019 activities such as the acquisition of Medisource Partners for medical and surgical distribution, funding arrangements totaling over $42 million for operations and clinical advancements including AE37 combination trials with Keytruda, purchase agreements for pharmacy operations, and strategic collaborations like a $50 million licensing deal with Chinese partners for Ii-Key vaccine platform expansion into infectious diseases and oncology.
Contrasting Zymeworks (NASDAQ:ZYME) and Generex Biotechnology (OTCMKTS:GNBT)
NuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm
Generex Biotechnology Subsidiary NuGenHealth Contracts with Florida Health Care Associates to Provide Remote Patient Monitoring (RPM) Services
Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Thursday May 6, 2021 at 9:00 AM
Last Chance for Children is Proud to Announce its Partnership with Generex Biotechnology & NuGenerex Immuno-Oncology to SAFELY and EFFECTIVELY Vaccinate Children and Pregnant Women
Generex Biotechnology Announces Shareholder Conference Call Scheduled for Thursday May 6, 2021
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Complete Vaccine™ Development Program
Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Friday February 5, 2021 at 9:00 AM
Generex Biotechnology Announces Investor Conference Call Scheduled for Friday February 5, 2021 at 9:00 AM
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete Vaccine™
Generex and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand
Generex signs Worldwide Licensing Deal with China Partners on the Development of an Ii-Key-H1 Swine Influenza Vaccine
Generex Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform
Generex Announces the Signing of a Framework Agreement with The China CDC, Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co., Ltd on the Cooperative Development of Ii-Key Vaccines
NuGenerex Immuno-Oncology Announces the Launch of a New Corporate Website
Generex Sees Way Forward With Long-Lasting Covid-19 Vaccine
Generex Subsidiary NuGenerex Immuno-Oncology Announces Appointment of Dr. Tamera Coyne-Beasley to the Scientific Advisory Board for its COVID-19 Vaccine Development Program